Artiva Biotherapeutics, Inc. (ARTV)
Healthcare
- Fundamental
- 3
- Sentiment
- 4
- Technical
- 2
Do Nothing: 20-day average dollar volume $4.04M is below the $5M liquidity floor; no entry qualifies - a pullback/oversold limit is additionally barred by the trend-alignment gate (price 6.06 < SMA50 9.43 with MACD < 0), and a breakout buy-stop is barred by the same liquidity floor.
Company overview
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies for autoimmune disorders and cancer. Its lead product, AB-101, is an off-the-shelf NK cell therapy targeting a range of autoimmune diseases and B-cell non-Hodgkin lymphoma. The company also develops AB-201 and AB-205, both allogeneic CAR-NK cell candidates, and is headquartered in San Diego, California.
Fundamental
fairThe company has a strong balance sheet but no revenue, with a cash runway into 2029 and ongoing losses.
Mixed fundamentals with an exceptionally strong balance sheet: this pre-revenue, clinical-stage cell-therapy developer holds $349.4M of cash and investments after a $300M May 2026 equity raise, carries no funded debt, and reports a cash runway into 2029 - versus zero product revenue, a TTM net loss of about $90.8M, and a TTM free-cash-flow yield of -33%. SEC filings show no going-concern, covenant, or litigation issues; the principal risks are binary Phase 3 clinical outcomes (primary data expected H2 2028) and continued dilution. Discounted-cash-flow model values sit about 89% below the quote, but that model is structurally unreliable for a company with no revenue and heavy burn.
Sentiment
goodUpcoming data events and stable media sentiment support a constructive outlook.
Dominant driver is the announced AlloNK autoimmune data flow — updated Sjögren disease data (2026-10-01) plus multiple ACR Convergence 2026 presentations and a November 9 clinical webcast ahead (all announced-tier) — on a stable-to-mildly-positive media tape (delta flat: baseline +0.10 to scoring +0.14) with the Red-Flag Screen clean; no caps applied.
Technical
weakThe stock is in a strong downtrend with limited bounce potential, trading below key moving averages.
Weak-bearish, bounce-only chart: price 6.06 trades below SMA20 7.09, SMA50 9.43, SMA200 7.97, EMA9 6.57 and EMA21 7.33 after a six-week decline from ~11.30; ADX14 54.27 confirms a strong established downtrend and MACD (-0.87 / -0.88 / 0.00) remains below zero. The only constructive elements are deep oversold readings (RSI14 25.81, Williams %R -86.45) with a two-session stabilization attempt - a reflex-bounce case at best, hence score 2. Independent of the chart, the trade is blocked: avgDollarVolume20 $4.04M is below the $5M liquidity floor, and a pullback/oversold limit would additionally fail the trend-alignment gate.
You’re looking at 2026-10-15 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.

